Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Saved in:
| Title: | Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. |
|---|---|
| Authors: | Eron JJ; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA., Cook PP; Division of Infectious Diseases, East Carolina University, Greenville, North Carolina, USA., Mehrotra ML; Cinical Research, Gilead Sciences, Inc, Foster City, California, USA., Huang H; Biostatistics, Gilead Sciences, Inc, Foster City, California, USA., Caskey M; Laboratory of Molecular Immunology, Rockefeller University, New York, New York, USA., Crofoot GE; Crofoot MD Clinic and Research Center, Houston, Texas, USA., Gorgos L; AXCES Research Group, Santa Fe, New Mexico, USA., VanderVeen LA; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA., Zheng Y; Clinical Pharmacology, Gilead Sciences, Inc, Foster City, California, USA., Collins SE; Clinical Development, Gilead Sciences, Inc, Foster City, California, USA., Osiyemi OO; Triple O Research Institute PA, West Palm Beach, Florida, USA., Brinson C; Central Texas Clinical Research, Austin, Texas, USA., DeJesus E; Orlando Immunology Center, Orlando, Florida, USA. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2025 Jul 11; Vol. 231 (6), pp. 1440-1444. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
